Literature DB >> 2140808

Specific cytotoxic effect of neocarzinostatin conjugated to monoclonal antibody A7 on human pancreatic carcinoma.

E Otsuji1, T Takahashi, T Yamaguchi, N Yamaguchi, J Imanishi.   

Abstract

The anti-cancer drug neocarzinostatin (NCS) was bound covalently to the monoclonal antibody A7 to form the conjugate A7-NCS. This antibody was produced by fusing the spleen cells of a mouse immunized against human colonic carcinoma with murine myeloma cells and reacts with a high percentage of human pancreatic carcinoma cell lines and with no normal human pancreas tissue by immunoperoxidase staining. The cytotoxic effect of A7-NCS was tested by measuring the inhibition of 3H-thymidine incorporation into human pancreatic carcinoma cells. The A7-NCS was approximately 2.7 times as effective as free NCS against human pancreatic carcinoma cells which reacted with the monoclonal antibody A7. A7-NCS had almost the same cytotoxicity a free NCS on human pancreatic carcinoma cells which did not react with the monoclonal antibody A7. A7-NCS appeared to be potentially useful as a conjugate for immunotargeting chemotherapy against pancreatic carcinoma.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2140808     DOI： 10.1007/bf02776823

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN： 0435-1339


  20 in total

1.  Stimulation of low density lipoprotein receptor activity by conditioned medium from a human cancer cell line.

Authors:  O Shiroeda; N Yamaguchi; K Kawai
Journal:  Cancer Res       Date:  1987-09-01       Impact factor: 12.701

2.  [Neocarzinostatin. A new chemotherapeutic approach to acute leukemia (author's transl)].

Authors:  K Hiraki; O Kamimura; I Takahashi; T Nagao; K Kitajima; S Irino
Journal:  Nouv Rev Fr Hematol       Date:  1973 Jul-Aug

3.  Acid protease secreted from human pancreatic carcinoma cell line HPC-YT into serum-free, chemically defined medium.

Authors:  N Yamaguchi; K Kawai
Journal:  Cancer Res       Date:  1986-10       Impact factor: 12.701

4.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

5.  Fluorophotometric enzyme immunoassay of neocarzinostatin using peroxidase as a label.

Authors:  K Matsuoka; M Maeda; A Tsuji
Journal:  Chem Pharm Bull (Tokyo)       Date:  1980-06       Impact factor: 1.645

6.  Chemotherapy for bladder cancer with neocarzinostatin: evaluation of systemic administration.

Authors:  S Sakamoto; J Ogata; K Ikegami; H Maeda
Journal:  Eur J Cancer       Date:  1980-01       Impact factor: 9.162

7.  Effect of nonprotein chromophore removal on neocarzinostatin action.

Authors:  M A Napier; L S Kappen; I H Goldberg
Journal:  Biochemistry       Date:  1980-04-29       Impact factor: 3.162

8.  Biological activity of the antitumor protein neocarzinostatin coupled to a monoclonal antibody by N-succinimidyl 3-(2-pyridyldithio)-propionate.

Authors:  G Jung; W Köhnlein; G Lüders
Journal:  Biochem Biophys Res Commun       Date:  1981-07-30       Impact factor: 3.575

9.  In vitro inhibition of human leukemic cells (CCRF-CEM) by agarose-immobilized neocarzinostatin.

Authors:  H Lazarus; V Raso; T S Samy
Journal:  Cancer Res       Date:  1977-10       Impact factor: 12.701

Review 10.  Neocarzinostatin in cancer chemotherapy (review).

Authors:  H Maeda
Journal:  Anticancer Res       Date:  1981       Impact factor: 2.480
View more
  6 in total

1.  Distribution of neocarzinostatin conjugated to biotinylated chimeric monoclonal antibody Fab fragments after administration of avidin.

Authors:  E Otsuji; T Yamaguchi; H Matsumura; K Yamamoto; H Tsuruta; Y Yata; H Nishi; K Okamoto; K Kitamura; T Takahashi
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

2.  Effects of neocarzinostatin-chimeric Fab conjugates on the growth of human pancreatic carcinoma xenografts.

Authors:  E Otsuji; T Yamaguchi; H Tsuruta; Y Yata; H Nishi; K Okamoto; K Taniguchi; M Kato; T Kotani; K Kitamura; T Takahashi
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

3.  In vitro reactivity and in vivo biodistribution of the monoclonal antibody A7 using human gastric carcinoma cell lines.

Authors:  N Yamaoka; T Yamaguchi; E Otsuji; M Kato; T Kotani; K Kitamura; T Takahashi
Journal:  Br J Cancer       Date:  1994-09       Impact factor: 7.640

4.  Efficacy and specificity of a monoclonal antibody-drug conjugate in chemotherapy by intratumoral injection.

Authors:  K Kitamura; T Takahashi; T Miyagaki; N Yamaoka; H Tsurumi; E Ohtsuji; M Kamiguchi; A Noguchi; T Yamaguchi
Journal:  Jpn J Cancer Res       Date:  1992-07

5.  Biodistribution of neocarzinostatin conjugated to chimeric Fab fragments of the monoclonal antibody A7 in nude mice bearing human pancreatic cancer xenografts.

Authors:  E Otsuji; T Yamaguchi; N Yamaoka; K Taniguchi; M Kato; T Kotani; K Kitamura; T Takahashi
Journal:  Jpn J Cancer Res       Date:  1994-05

6.  Enhanced tumor localization of radiolabeled Fab fragments of monoclonal antibody A7 in nude mice bearing human pancreatic carcinoma xenografts.

Authors:  E Otsuji; T Yamaguchi; N Yamaoka; M Kato; T Kotani; K Kitamura; N Yamaguchi; T Takahashi
Journal:  Jpn J Cancer Res       Date:  1993-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.